Oncopeptides

Oncopeptides AB, Stockholm‑based biotech, pioneers peptide‑drug conjugates for hematologic cancers. Its approved melflufen (Pepaxti) treats relapsed/refractory multiple myeloma, while modular PDC and SPiKE platforms expand the pipeline into solid tumors and glioblastoma.

Headquarters: Sweden (SWE)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 75
HQ: Stockholm

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ONCO	Oncopeptides Cap: 0.9B	EQUITY	STO	SEK	SE0009414576	Active	📈